Global Pneumonia Vaccines Market to reach a market size of $9.6 billion by 2025- KBV Research

The Global Pneumonia Vaccines Market size is expected to reach $9.6 billion by 2025, rising at a market growth of 5.1% CAGR during the forecast period.
 
NEW YORK - Aug. 20, 2019 - PRLog -- According to a new report Global Pneumonia Vaccines Market, published by KBV research, The Global Pneumonia Vaccines Market size is expected to reach $9.6 billion by 2025, rising at a market growth of 5.1% CAGR during the forecast period.

The North America market dominated the Global Pneumococcal Conjugate Vaccine (PCV) Market by Region in 2018, growing at a CAGR of 2.8 % during the forecast period. The Europe market is expected to witness a CAGR of 3.6% during (2019-2025). Additionally, The Asia Pacific market is expected to witness a CAGR of 5.3% during (2019-2025).

The Prevnar 13 market dominated the Global Pneumonia Vaccines Market by Product Type in 2018, growing at a CAGR of 4.1 % during the forecast period. The Synflorix market is expected to witness a CAGR of 7.5% during (2019-2025). Additionally, The Pneumovax23 market is expected to witness highest CAGR of 8.5% during (2019-2025).

The Distribution Partner Companies market dominated the Global Pneumonia Vaccines Market by Distribution Channel in 2018, growing at a CAGR of 4.3 % during the forecast period. The Non-Governmental Organizations (NGO) market is expected to witness a CAGR of 6% during (2019-2025).

Full Report: https://www.kbvresearch.com/pneumonia-vaccines-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Glaxosmithkline Plc. (GSK), LG Corporation, Panacea Biotec Limited, Pfizer, Inc., Pnuvax Incorporated, Poonawalla Investments & Industries Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd., SK Holdings Co., Ltd., Walvax Biotechnology Co., Ltd. and MERCK & CO., Inc.

Global Pneumonia Vaccines Market Segmentation

By Vaccine Type


Pneumococcal conjugate vaccine (PCV)

Pneumococcal polysaccharide vaccine (PPSV/PPV)

By Product Type

Prevnar 13

Synflorix

Pneumovax23

By Sector

Public sector

Private sector

By Distribution Channel

Distribution partner companies

Non-governmental Organizations (NGO)

Government Authorities

By Geography

North America


US

Canada

Mexico

Rest of North America

Europe

Germany

UK

France

Russia

Spain

Italy

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

Singapore

Malaysia

Rest of Asia Pacific

LAMEA

Brazil

Argentina

UAE

Saudi Arabia

South Africa

Nigeria

Rest of LAMEA

Companies Profiled

Glaxosmithkline Plc. (GSK)

LG Corporation

Panacea Biotec Limited

Pfizer, Inc.

Pnuvax Incorporated

Poonawalla Investments & Industries Pvt. Ltd.

Shenzhen Kangtai Biological Products Co., Ltd.

SK Holdings Co., Ltd.

Walvax Biotechnology Co., Ltd.

Merck & Co., Inc.

Contact
KBV Research
***@kbvresearch.com
End
Source: » Follow
Email:***@kbvresearch.com Email Verified
Tags:Pneumonia Vaccines
Industry:Health
Location:New York City - New York - United States
Subject:Reports
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
KBV Research PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share